about
Accounting for individual differences and timing of events: estimating the effect of treatment on criminal convictions in heroin users.Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in Denmark, 2000-2010.Improved drug-use patterns at 6 months post-discharge from inpatient substance use disorder treatment: results from compulsorily and voluntarily admitted patientsMental distress following inpatient substance use treatment, modified by substance use; comparing voluntary and compulsory admissionsMethadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem.'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'.Cardiovascular disease among people with drug use disorders.Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study.The use of public health infrastructure probably the best strategy for national and large-scale naloxone distribution programmes.Confirming the factor structure of a generic quality of life instrument among pre-treatment substance use disorder patientsPerformance of the WHOQOL-BREF among Norwegian substance use disorder patientsNaloxone distribution and possession following a large-scale naloxone programme.Hazardous Drinking Prevalence and Correlates in Older New Zealanders: A Comparison of the AUDIT-C and the CARETReadiness to change among involuntarily and voluntarily admitted patients with substance use disordersPrescribed opioid analgesic use developments in three Nordic countries, 2006-2017Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study[Re: Patients who terminate OMT--how do they fare?]
P50
Q33693992-7766AF10-D49C-43F5-B7FC-3D2AF0078C4FQ36032982-44DE0350-6951-4050-A358-A4C83D9ED83AQ36083200-AC736EB8-0A22-4B73-A350-A6B6B28697F5Q36238898-21FD92BD-6435-4581-BDD6-5DEE0F451FEDQ37248049-C9466DC3-23B6-485E-97B5-2502CF3564CFQ37370423-CE497B74-2223-4428-91E5-C13C33D1D0E7Q41647178-7A558ACB-9869-4771-B26A-BCCBEE836C5FQ44345542-9DEFA6D2-9517-4167-BC6B-FA58B5717675Q50856219-5299537C-3F9C-467C-907F-0CB0B151AE25Q64052576-C69B75A8-5A2F-4B0D-BF94-487B7F18DBACQ64066524-6AEFD091-2A86-438E-AF24-559FF6304D6AQ64972943-889DB5B2-EB97-4956-8B9C-E783675C65F6Q91144262-47B86F71-7DE9-42D7-ABDB-FA562B7126D1Q91149626-1316A652-643D-4568-BEDD-E832E4076FD4Q91196639-6347C103-3530-4080-852B-24F1CBDEB192Q91561247-7BEED563-54B4-41B2-A46B-1DDB8DF2BEA4Q95510995-A9A9F99B-C7E9-4EAE-9341-F1D3A822261E
P50
description
researcher (ORCID 0000-0002-2421-4201)
@en
name
Thomas Clausen
@en
type
label
Thomas Clausen
@en
prefLabel
Thomas Clausen
@en
P31
P496
0000-0002-2421-4201